Safety and Tolerability of Monoclonal Antibody Therapies for Treatment of COVID-19 in Pediatric Patients. Issue 12 (13th July 2021)

• Record Type: Journal Article
• Authors: Mak, Gregory; Dassner, Aimee M.; Hammer, Benjamin M.; Hanisch, Benjamin R.
• Is Part Of: Pediatric infectious disease journal. Volume 40:Issue 12(2021)
• Page Start: e507
• Page End: e509
• Publication Date: 2021-07-13
• Subjects: monoclonal antibody -- pediatrics -- COVID-19; Communicable diseases in children -- Periodicals; Infection in children -- Periodicals; 618.929
• DOI: 10.1097/INF.0000000000003263
• Languages: English
• ISSNs: 0891-3668

Abstract

Abstract : There is a little data regarding safety or efficacy of monoclonal antibody treatment for mild-to-moderate COVID-19 in pediatric patients despite it being frequently used in adults. This retrospective study of 17 patients with mild-to-moderate COVID-19 who received monoclonal antibody therapy found that the treatment was well tolerated, safe, and may be effective in halting progression to severe disease.